---
title: "Analyst Maintains Buy on Sol-Gel, Citing SGT-610 Progress and Solid Cash Runway with Unchanged $184 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287986881.md"
description: "Analyst Patrick Dolezal from LifeSci Capital maintains a Buy rating on Sol-Gel Technologies with a $184 price target, citing progress in the Phase 3 trial of SGT-610 and a solid cash runway. He notes the trial is on schedule for a key readout in Q4 2026 and highlights potential royalty revenue from licensing deals. With $52.8 million in cash, the company is well-positioned to reach the trial's data inflection point."
datetime: "2026-05-29T00:15:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287986881.md)
  - [en](https://longbridge.com/en/news/287986881.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287986881.md)
generator: "portal-rs"
---

# Analyst Maintains Buy on Sol-Gel, Citing SGT-610 Progress and Solid Cash Runway with Unchanged $184 Price Target

Sol-Gel Technologies, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on the stock and has a $184.00 price target.

### Memorial Day Sale – Claim 70% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Patrick Dolezal has given his Buy rating due to a combination of factors related to Sol-Gel’s lead asset and financial position. He emphasizes that the pivotal Phase 3 trial of SGT-610 in Gorlin syndrome remains on schedule for a key topline readout in Q4 2026, and that recent U.S. patent progress could secure market exclusivity for the product candidate into 2044, strengthening its long‑term commercial potential.

In addition, he highlights Sol-Gel’s ex-U.S. licensing deals for Twyneo and Epsolay, which could collectively contribute up to roughly $10 million in annual high-margin royalty revenue, helping to support the company’s cash runway. With about $52.8 million in cash and equivalents and an estimated 1.8 years of funding at the current burn rate, he views the balance sheet as sufficient to reach the SGT-610 Phase 3 data inflection, and accordingly maintains a Buy rating and an unchanged $184 price target.

### Related Stocks

- [SLGL.US](https://longbridge.com/en/quote/SLGL.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

- [Sol-Gel Therapeutics: Steady SGT-610 Execution and Capital-Efficient Growth Strategy Drive Price Target Increase to $195 and Support Buy Rating](https://longbridge.com/en/news/296514505.md)
- [Opaleye Management reports $68,006 purchase of Sol-Gel Technologies common shares](https://longbridge.com/en/news/295970228.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**